Compounded vs. FDA-approved GLP-1s: What you need to know
Updated May 5, 2026
Bottom line
Compounded semaglutide and tirzepatide are made by compounding pharmacies, not pharmaceutical companies. They were widely available during the FDA shortage period from 2022 to 2024. Both shortages have since been declared over, and in April 2026 the FDA proposed to formally exclude semaglutide, tirzepatide, and liraglutide from the list of bulk substances that outsourcing facilities can use. The legal pathway for compounded GLP-1s has narrowed substantially. Understanding the rules and what to ask before ordering helps you decide if it's still the right path.
If you've shopped GLP-1 medications online, you've probably seen "compounded" semaglutide or tirzepatide advertised at a fraction of brand-name prices. The honest answer to "is it safe, does it work, is it legal" is "it depends, and the rules are changing."
Why it matters
The price difference is significant. Compounded versions often run $200 to $400 per month compared to $1,000 or more for brand-name medications without insurance, although brand-name drug manufacturers are beginning to reduce cash-pay prices. For people who can't get insurance coverage and can't afford the list price, compounding has been the access point. Whether that path is still open depends on which medication, what type of compounding pharmacy is involved, and the regulatory situation at the time you order.
What "compounded" actually means
Compounding pharmacies prepare medications for individual patients. Traditional compounding fills a real gap: making liquid versions for patients who can't swallow pills, removing allergens, adjusting doses for children. Compounding is regulated under federal law, specifically Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
Compounded semaglutide and tirzepatide are different from traditional compounding. They aren't usually custom adjustments for individual patients. They're often produced at scale and shipped to people who could otherwise take the FDA-approved version, but find it too expensive or unavailable.
Go deeper: 503A and 503B compounding, and why it matters
Federal law defines two main types of compounders, each with different rules.
503A compounding pharmacies are state-licensed pharmacies that make compounds for specific patients with prescriptions. They aren't required to register with the FDA. They generally cannot legally produce a "copy" of an FDA-approved commercial drug except in narrow circumstances.
503B outsourcing facilities can produce compounds in larger quantities without a patient-specific prescription. They voluntarily register with the FDA and are subject to FDA inspection and Current Good Manufacturing Practice standards. 503B facilities can only compound from bulk substances on the FDA's 503B bulks list, or from drugs on the FDA's shortage list at the time of compounding.
Most of the compounded GLP-1 supply during the shortage period came through 503B facilities and through 503A pharmacies operating under shortage-related allowances. Both pathways have been narrowing.
Go deeper: how compounding became widespread for GLP-1s
When Ozempic, Wegovy, Mounjaro, and Zepbound went into shortage from 2022 to 2024, the FDA placed the active ingredients on its drug shortage list. Federal law allows compounding pharmacies to produce drugs in shortage. This created a legal window for compounded GLP-1s.
The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in early 2025. Once a shortage ends, the shortage-related allowance for compounding closes.
In April 2026, the FDA went further. The agency proposed to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, finding "no clinical need" for outsourcing facilities to compound these drugs from bulk substances. The proposal is open for public comment through June 29, 2026, after which the FDA will make a final decision. If adopted, 503B outsourcing facilities would not be able to compound these drugs from bulk ingredients regardless of shortage status.
This does not change the rules for 503A traditional compounding pharmacies in the same way, though 503A pharmacies still cannot produce copies of approved drugs except in limited situations. The practical effect is that the legal pathway for compounded GLP-1 access has narrowed substantially since 2024 and is likely to narrow further if the 503B proposal is finalized.
Quality and safety
FDA-approved medications go through manufacturing oversight, batch testing, and post-market surveillance. Compounded medications are regulated by state pharmacy boards and (for larger 503B facilities) the FDA, but with different standards. Quality varies by pharmacy.
Reports on compounded GLP-1 quality are mixed. Some patients report consistent results similar to brand-name medication. Others report inconsistent dosing, unexpected side effects, or vials that look different batch to batch. Independent testing has found variation in actual concentration compared to label claim.
Worth knowing
"Semaglutide salts" (semaglutide acetate, semaglutide sodium) are different chemical forms from the semaglutide in Ozempic and Wegovy. The FDA has stated these salt forms are not legally compoundable as substitutes for the approved medication. If a compounder offers semaglutide and the form isn't the same as the FDA-approved version, that's a flag.
Go deeper: what to ask before ordering
Is this a 503A pharmacy or a 503B outsourcing facility?
What is the legal basis the pharmacy is operating under right now? (Patient-specific prescription under 503A, or another pathway?)
Is the active ingredient pure semaglutide or tirzepatide, or a salt form?
What concentration is the medication, and how is dosing calculated?
Is there a financial relationship between the prescriber and the compounder?
What does the patient instruction look like, and is there clinical follow-up?
Insurance and brand savings programs
If cost is the main reason for considering compounded medication, manufacturer savings programs are worth checking first. Novo Nordisk runs a Wegovy savings program for eligible patients, and Eli Lilly offers a Zepbound savings card and LillyDirect direct-pay option. Coverage depends on insurance type and indication. The savings aren't dramatic for everyone, but they're meaningfully better than list price for many.
What this means for you
The compounded GLP-1 landscape has shifted significantly. The shortage-driven legal pathway closed in late 2024 and early 2025. The FDA's April 2026 proposal would close the 503B bulks list pathway as well, pending public comment and final action. Some 503A pharmacies are still compounding, but the legal questions are sharper than they were even a year ago. If you're considering compounded medication, talk to your prescriber, ask the pharmacy specific questions about the legal pathway they're operating under, and verify the current FDA status before ordering. The rules are continuing to change.